Indeed, the age-standardised prevalence of AMD-related blindness has decreased by approximately 30%, likely due to the widespread implementation of anti-vascular endothelial growth factor treatment for exudative AMD [26]. This evidence concerns the gene VEGFA and blindness (disorder).